Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas

Model scores of the 29,894 trials active now.

Model score 24% for any early termination, 11% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 23% of the time (1,629 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2021-02-14. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: glioblastomamg dlmrigliomacalled
  Phrases that lowered it: daysof studygeneraldruglymphoma
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1 (lowers risk) · Design
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 26.9% (raises risk) · Drug's FDA history
• Responsible party: sponsor investigator (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Drug's FAERS reports marked serious: 98.2% (raises risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Sponsor's past trials: 0 (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Blinding: none (raises risk) · Design
• Number of arms: 2 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma NCT01051557 · started 2010 · scored riskier than 33% of active trials completed
• Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab NCT01931098 · started 2015 · scored riskier than 56% of active trials completed
• Radiation Therapy and Temsirolimus or Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma NCT01019434 · started 2009 · scored riskier than 95% of active trials completed
• Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas NCT02313272 · started 2015 · scored riskier than 88% of active trials completed
• Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma NCT01849146 · started 2013 · scored riskier than 98% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.